Lurasidone hydrochloride (HCl) is an atypical antipsychotic medication primarily used for the treatment of schizophrenia and bipolar depression. It works by modulating dopamine D2 and serotonin 5-HT2A receptors, helping to balance neurotransmitters in the brain. Unlike older antipsychotics, lurasidone has a more selective receptor-binding profile, which reduces the risk of motor-related side effects while still effectively managing hallucinations, delusions, mood instability, and cognitive impairments. It is commonly prescribed for adult and adolescent patients with schizophrenia and is also approved for bipolar depression as monotherapy or in combination with mood stabilizers like lithium or valproate.

One of the key advantages of lurasidone over other atypical antipsychotics is its favorable metabolic profile, meaning it has a lower risk of weight gain, increased blood sugar, and lipid abnormalities compared to many other antipsychotic medications. This makes it a preferred option for patients who are concerned about metabolic side effects. Additionally, lurasidone has been found to improve cognitive function and overall daily functioning in patients, allowing them to maintain a better quality of life. Unlike some other medications in its class, it has minimal sedative effects, making it a better choice for individuals who want to avoid excessive drowsiness while undergoing treatment. However, because lurasidone requires food intake for optimal absorption, patients need to take it with at least 350 calories to ensure maximum effectiveness.

Despite its benefits, lurasidone can cause certain side effects, including nausea, dizziness, restlessness (akathisia), and sleep disturbances. In some cases, it may also lead to increased anxiety or agitation, particularly in the early stages of treatment. As with other antipsychotic medications, there is a risk of tardive dyskinesia (involuntary movements) and neuroleptic malignant syndrome (a rare but serious neurological condition), though the incidence is lower compared to older antipsychotics.

(1R,2R)-1,2-Cyclohexanedimethanol	65376-05-8
(3aR,4S,7R,7aS)4,7-methano-1H-isoindole-1,3(2H)-di-one	14805-29-9